ViMRT
}  
 
Home   
< Docs   

 HBV mutation literature information.


  Low efficacy of entecavir therapy in adefovir-refractory hepatitis B patients with prior lamivudine resistance.
 PMID: 19678894       2010       Journal of viral hepatitis
Abstract: Higher pretreatment ALT (P = 0.039) and the presence of the rtL180M mutation (P = 0.038) were associated with an initial virologic response.


  Occult hepatitis B virus infection and lamivudine-resistant mutations in isolates from renal patients undergoing hemodialysis.
 PMID: 19817965       2010       Journal of gastroenterology and hepatology
Abstract: Four of these six HBV isolates contained mutations associated with lamivudine resistance in the DNA polymerase (two with L180M/M204V and two with rt173V/180M/204V) and a specific substitution (Y100C) in the HBV small surface protein.


  Differential impact of immune escape mutations G145R and P120T on the replication of lamivudine-resistant hepatitis B virus e antigen-positive and -negative strains.
 PMID: 19889778       2010       Journal of virology
Abstract: Replication-competent HBV strains with sG145R or sP120T and LAM resistance (rtM204I or rtL180M/rtM204V) were generated on an HBeAg-positive and an HBeAg-negative background with precore (PC) and basal core promoter (BCP) mutants.


  Mechanism of entecavir resistance of hepatitis B virus with viral breakthrough as determined by long-term clinical assessment and molecular docking simulation.
 PMID: 19933798       2010       Antimicrobial agents and chemotherapy
Abstract: Multivariate logistic regression analysis adjusted for age, gender, HBV DNA levels, and LVD resistance (LVDr) (L180M and M204V, but not M204I) indicated that T184 substitutions and S202G (not S202C) were a significant factor for BT (adjusted odds ratio [OR], 141.12, and 95% confidence interval [CI], 6.94 to 2,870.20; OR, 201.25, and 95% CI, 11.22 to 3608.65, respectively).
Abstract: Our data suggest that the low binding affinity of ETV-TP for the HBV RT, involving conformational change of the binding pocket of HBV RT by L180M, M204V plus T184L, and S202G, could induce BT.


  Prevalence and clinical characterization of patients with acute hepatitis B induced by lamivudine-resistant strains.
 PMID: 20074155       2010       Journal of gastroenterology and hepatology
Abstract: LMV-resistance mutations (L180M, M204I) were detected in a patient with subgenotype C2 who had acute self-limited hepatitis.
Abstract: The other patient with LMV-resistance mutations (L180M, M204V) was infected with subgenotype A2 and had severe hepatitis.


  Hepatitis B viral surface mutations in patients with adefovir resistant chronic hepatitis B with A181T/V polymerase mutations.
 PMID: 20119580       2010       Journal of Korean medical science
Introduction: Patients with lamivudine (LMV)-resistant rtM204I/V (+-rtL180M) mutations in the catalytic tyrosine-methionine-aspartate-aspartate (YMDD) motif are less responsive to entecavir (ETV).
Method: These patients developed ADV resistance while undergoing ADV monotherapy as rescue therapy for LMV-resistant HBV (rtM204I/V+-rtL180M).


  Mechanistic characterization and molecular modeling of hepatitis B virus polymerase resistance to entecavir.
 PMID: 20169198       2010       PloS one
Introduction: Both patients were infected with HBV with M204V+L180M LVDr substitutions at study entry and developed additional substitutions T184G & S202I, or M250V on therapy.
Introduction: In addition, ETVr substitutions in isolates with only the M204I substituted LVDr HBV and not the M204V+L180M LVDr virus, phenotypic resistance to ETV is diminished.
Method: Additional HBV-RT homology models were constructed with the LVD (M204V+L180M) and adefovir (A181T/V and N236T) resistance substitutions, and the ETVr signature sub


  Hepatitis B virus drug resistance in HIV-1-infected patients taking lamivudine-containing antiretroviral therapy.
 PMID: 20377434       2010       AIDS patient care and STDs
Abstract: All 19 patients with HBV-DR had lamivudine resistance with the mutations as follows: M204V/I (95%), L180M/A181T (95%), L80V/I (47%), V173L (32%), and N236T (21%).


  [Polymerase region mutations and hepatitis B virus genotypes in chronic hepatitis B patients with poor response to lamivudine].
 PMID: 20380793       2010       Zhonghua gan zang bing za zhi
Abstract: The overall incidence rate of A181V/T mutation in genotype C (5.3%) was significantly higher than that in genotype B (0.4%) (x2=12.23, P less than 0.01), but the incidence rate of M204I/V, L180M, T184A/G/I/S, S202G/I and V173L mutations was not significantly different between genotype B and C (each P more than 0.05).


  Monitoring of hepatitis B virus surface antigen escape mutations and concomitantly nucleos(t)ide analog resistance mutations in Turkish patients with chronic hepatitis B.
 PMID: 20382061       2010       International journal of infectious diseases
Abstract: Interestingly, the treatment-naive patients had preexisting drug resistance mutations related to lamivudine (rtL180M+rtM204I), adefovir (rtA181V, rtQ215S, rtI233V), entecavir (intermediate susceptibility with rtL180M+rtM204IHBV variant), telbivudine (rtL180M+rtM204I), and tenofovir (rtA194T).



Browser Board

 Co-occurred Entities




   Filtrator